Doctor, Chief Physician, currently serving as Director of the Interventional Therapy Department, Inner Mongolia Hospital, Peking University Cancer Hospital. **Specialties:** Image-guided minimally invasive interventional oncology treatments, including transarterial chemoembolization, ablation, and radioactive seed implantation for malignant tumors such as primary liver cancer, metastatic liver cancer, and lung cancer, as well as interventional treatments for tumor-related complications. **Professional Affiliations:** Standing Committee Member and Secretary-General, Liver Cancer Minimally Invasive Interventional Therapy Committee, Beijing Cancer Prevention and Treatment Society; Committee Member and Secretary, Tumor Interventional Therapy Committee, Chinese Anti-Cancer Association; Committee Member, Tumor Cryoablation and Targeted Therapy Committee, National Strategic Alliance for Technological Innovation in Minimally Invasive Tumor Therapy; Expert Database Committee Member, Tumor Ablation Therapy Technology Quality Control Center, Beijing Traditional Chinese Medicine Association. **Recent Publications (Papers, Treatises):** 1. Jianhai Guo, Ronald S Arellano*. Percutaneous microwave ablation of stage T1a renal cell carcinoma: intermediate results on safety, technical feasibility and clinical outcomes of 119 tumors. Am J Roentgenol. 2021;216:117-124. (SCI-indexed, IF: 3.959, First Author) 2. Jianhai Guo, Ronald S Arellano*. Percutaneous microwave ablation of stage T1b renal cell carcinoma: short-term assessment of technical feasibility, short-term oncologic outcomes, and safety. J Endourol. 2020 Oct;34(10):1021-1027. (SCI-indexed, IF: 2.942, First Author) 3. Jianhai Guo#, Shaoxing Liu#, Song Gao, Fuxin Kou, Xin Zhang, Peng Liu, Renjie Yang, Xu Zhu*. γ-glutamyltranspeptidase as a prognostic biomarker in advanced hepatocellular carcinoma receiving transarterial chemoembolization. J Vasc Interv Radiol. 2021 Mar;32(3):419-428. (SCI-indexed, IF: 3.464, First Author) 4. Guo JH#, Liu SX#, Gao S#, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu Peng, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X*. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol. 2020;26(27):3975-3988. (SCI-indexed, IF: 5.742, First Author) 5. Jianhai Guo#, Hangyu Zhang#, Song Gao, Peng-Jun Zhang, Xiao-Ting Li, Hui Chen, Xiao-Dong Wang, Xu Zhu*. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol. 2017;23(8):1406-1411. **Research Projects:** 1. Peking University Cancer Hospital Clinical Research Special Fund, Randomized controlled study of bevacizumab combined with irinotecan drug-eluting bead embolization for colorectal cancer liver metastases, 2021/12-2024/11, 100,000 RMB, Principal Investigator. 2. National Natural Science Foundation of China (General Program), 81571781, Study on the molecular mechanisms and clinical value of FOXB2 and DBX2 in the development and progression of primary hepatocellular carcinoma, 2017/05-2020/06, 500,000 RMB, Participant. 3. Capital Health Development Research Special Fund (Independent Innovation Project), 2014-2-2154, Randomized controlled study of hepatic arterial infusion of oxaliplatin and fluorouracil after TACE for intermediate-advanced primary liver cancer, 2014/09-2017/12, 400,000 RMB, Completed, Key Participant. 4. National "12th Five-Year Plan" Major Special Sub-project, 2012ZX10002015-003, Clinical Phase IV study of Licartin combined with TACE for primary liver cancer, 2017/05-2020/06, 500,000 RMB, Participant.